Case Report
Copyright ©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Cases. Sep 16, 2022; 10(26): 9510-9517
Published online Sep 16, 2022. doi: 10.12998/wjcc.v10.i26.9510
Intravitreous injection of conbercept for bullous retinal detachment: A case report
Xiao-Li Xiang, Yi-Hong Cao, Ting-Wang Jiang, Zheng-Ru Huang
Xiao-Li Xiang, Yi-Hong Cao, Zheng-Ru Huang, Department of Ophthalmology, The Affiliated Changshu Hospital of Xuzhou Medical University, Changshu 215500, Jiangsu Province, China
Ting-Wang Jiang, Department of Key Laboratory, The Affiliated Changshu Hospital of Xuzhou Medical University, Changshu 215500, Jiangsu Province, China
Author contributions: Xiang XL, Cao YH, and Huang ZR contributed to conception and design; Xiang XL, and Jiang TW contributed to data collection and collation; Xiang XL contributed to manuscript writing; Huang ZR contributed to definition of intellectual content, data interpretation and final review of the manuscript; all authors have read and approved the final manuscript.
Supported by Guiding Project of Changshu Health Committee, No. CSWZD202021; Project of the Affiliated Changshu Hospital of Xuzhou Medical University, No. CSEY202125.
Informed consent statement: The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee(s) and with the Helsinki Declaration (as revised in 2013). Written informed consent was obtained from the patient for publication of this case report and accompanying images. A copy of the written consent is available for review by the editorial office of this journal.
Conflict-of-interest statement: All authors have completed the ICMJE uniform disclosure form. The authors declare that they have no conflicts of interest to disclose.
CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See:
Corresponding author: Zheng-Ru Huang, MD, PhD, Chief Doctor, Professor, Department of Ophthalmology, The Affiliated Changshu Hospital of Xuzhou Medical University, No. 68 Haiyu South Road, Changshu 215500, Jiangsu Province, China.
Received: May 9, 2022
Peer-review started: May 9, 2022
First decision: June 16, 2022
Revised: June 25, 2022
Accepted: August 16, 2022
Article in press: August 16, 2022
Published online: September 16, 2022
Core Tip

Core Tip: The study patient exhibited a considerable improvement in retinal anatomical reduction after intravitreal injections of conbercept. Nevertheless, due to the the macular area destruction, we observed unsatisfactory improvement in best-corrected visual acuity. Based on the study findings, intravitreal injection of a vascular endothelial growth factor inhibitor may be a considered potent therapeutic option for cases of bullous retinal detachment of diffuse retinal pigment epitheliopathy. This treatment is uncomplicated and harmless and precludes adopting complex surgical techniques associated with high risk of complications.